Aprinocarsen
Title: Aprinocarsen
CAS Registry Number: 151879-73-1
CAS Name: d(P-Thio)(G-T-T-C-T-C-G-C-T-G-G-T-G-A-G-T-T-T-C-A)deoxyribonucleic acid
Manufacturers' Codes: CGP-64128A; ISI-641A; LY-900003
Literature References: Synthetic 20 base phosphorothioate antisense oligonucleotide designed to inhibit protein kinase C-a (PKC-a) expression. Prepn: C. F. Bennett, N. Dean, WO 9319203; eidem, US 5882927 (1993, 1999 both to Isis). Pharmacology: N. Dean et al., Cancer Res. 56, 3499 (1996). CGE determn in tissue: R. S. Geary et al., Anal. Biochem. 274, 241 (1999). Clinical pharmacology and evaluation in advanced cancer: J. Nemunaitis et al., J. Clin. Oncol. 17, 3586 (1999). Review of pharmacokinetics: P. L. Nicklin et al., Handb. Exp. Pharmacol. 131, 141-168 (1998). Review of development and clinical evaluations: J. T. Holmlund et al., Curr. Opin. Mol Ther. 3, 372-385 (1999); K. Li, J. Zhang, Curr. Opin. Invest. Drugs 2, 1454-1461 (2001).
 
Derivative Type: Sodium salt
CAS Registry Number: 331257-53-5
Manufacturers' Codes: ISIS-3521
Trademarks: Affinitac (Lilly); Affinitak (Lilly)
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Oligonucleotides.

Others monographs:
Ethylene OxideBenzethonium ChlorideBismuth SubsalicylateEthyl Tartrate, Acid
EritadenineDanofloxacinDithiazanine IodideXylyl Bromide
ErgotamineHydroxyamphetamineEthylene DichlorideDianisidine
PhosaloneInterleukin-4SesamexAnthracene
©2016 DrugLead US FDA&EMEA